{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:52:32Z","timestamp":1793839952324,"version":"4.6.1"},"reference-count":110,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-15-00432"],"award-info":[{"award-number":["22-15-00432"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Non-tuberculous mycobacteria are widely distributed in environments and are capable of infecting humans, particularly those with a compromised immune system. The most prevalent species that cause nontuberculous mycobacterial lung diseases are slow-growing bacteria from the Mycobacterium avium complex (MAC), mainly M. avium or M. intracellulare. The key treatment of MAC infections includes macrolides, ethambutol, and rifampicin; however, the therapy outcomes are unsatisfactory. Phenotypic drug susceptibility testing is a conditional recommendation prior to treatment, and critical concentrations for clarithromycin, amikacin, moxifloxacin, and linezolid have been established. In this review, data from studies on the determination of MIC of clinical isolates using the broth microdilution method were summarized. A significant variation in the MIC distributions from different studies was found. The main reasons could impact the findings: insufficient reproducibility of the phenotypic testing and variation in species lineages identified in different laboratories, which could have various intrinsic susceptibility to drugs. For most of the drugs analyzed, the MICs are too high, which could undermine the treatment efficiency. Further improvement of treatment outcomes demands the validation of microbiological resistance criteria together with the identification of molecular mechanisms of resistance.<\/jats:p>","DOI":"10.3390\/antibiotics11121756","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:56:26Z","timestamp":1670208986000},"page":"1756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Variability of Mycobacterium avium Complex Isolates Drug Susceptibility Testing by Broth Microdilution"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2040-0904","authenticated-orcid":false,"given":"Danila","family":"Zimenkov","sequence":"first","affiliation":[{"name":"Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1901623","DOI":"10.1183\/13993003.01623-2019","article-title":"On the Valid Publication of Names of Mycobacteria","volume":"54","author":"Tortoli","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chaptal, M., Andrejak, C., Bonifay, T., Beillard, E., Guillot, G., Guyomard-Rabenirina, S., Demar, M., Trombert-Paolantoni, S., Jacomo, V., and Mosnier, E. (2022). Epidemiology of Infection by Pulmonary Non-Tuberculous Mycobacteria in French Guiana 2008-2018. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010693"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"923968","DOI":"10.3389\/fpubh.2022.923968","article-title":"Trends and Species Diversity of Non-Tuberculous Mycobacteria Isolated From Respiratory Samples in Northern China, 2014\u20132021","volume":"10","author":"Sun","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lee, Y.-M., Kim, M.-J., and Kim, Y.-J. (2021). Increasing Trend of Nontuberculous Mycobacteria Isolation in a Referral Clinical Laboratory in South Korea. Med. Kaunas Lith., 57.","DOI":"10.3390\/medicina57070720"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1513\/AnnalsATS.201605-353OC","article-title":"Increasing Prevalence Rate of Nontuberculous Mycobacteria Infections in Five States, 2008\u20132013","volume":"13","author":"Donohue","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3201\/eid2311.170959","article-title":"Pulmonary versus Nonpulmonary Nontuberculous Mycobacteria, Ontario, Canada","volume":"23","author":"Brode","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4046\/trd.2018.0026","article-title":"Infection Source and Epidemiology of Nontuberculous Mycobacterial Lung Disease","volume":"82","author":"Jeon","year":"2019","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008\u20132015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"00207","DOI":"10.1183\/23120541.00207-2021","article-title":"The Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease in the Netherlands","volume":"7","author":"Schildkraut","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S1473-3099(15)00089-4","article-title":"Host Susceptibility to Non-Tuberculous Mycobacterial Infections","volume":"15","author":"Wu","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lake, M.A., Ambrose, L.R., Lipman, M.C.I., and Lowe, D.M. (2016). \u201cWhy Me, Why Now?\u201d Using Clinical Immunology and Epidemiology to Explain Who Gets Nontuberculous Mycobacterial Infection. BMC Med., 14.","DOI":"10.1186\/s12916-016-0606-6"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Griffith, D.E. (2019). Immune Dysfunction and Nontuberculous Mycobacterial Disease. Nontuberculous Mycobacterial Disease, Springer International Publishing. Respiratory Medicine.","DOI":"10.1007\/978-3-319-93473-0"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thorsurg.2018.09.006","article-title":"Nontuberculous Mycobacteria: Epidemiology and the Impact on Pulmonary and Cardiac Disease","volume":"29","author":"Drummond","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"ref_14","first-page":"358","article-title":"Diagnosis and Treatment of Patients with Pulmonary Nontuberculous Mycobacterial Diseases in Arkhangelsk, Russia","volume":"73","author":"Eliseev","year":"2019","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Falkinham, J.O. (2021). Ecology of Nontuberculous Mycobacteria. Microorganisms, 9.","DOI":"10.3390\/microorganisms9112262"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"00150","DOI":"10.1183\/23120541.00150-2017","article-title":"Prevention of Aerosol Isolation of Nontuberculous Mycobacterium from the Patient\u2019s Bathroom","volume":"4","author":"Morimoto","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fmed.2017.00027","article-title":"Infection Sources of a Common Non-Tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex","volume":"4","author":"Nishiuchi","year":"2017","journal-title":"Front. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100374","DOI":"10.1016\/j.onehlt.2022.100374","article-title":"High Rate of Reinfection and Possible Transmission of Mycobacterium avium Complex in Northeast Thailand","volume":"14","author":"Boonjetsadaruhk","year":"2022","journal-title":"One Health Amst. Neth."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e20220445","DOI":"10.1084\/jem.20220445","article-title":"Drug Development Challenges in Nontuberculous Mycobacterial Lung Disease: TB to the Rescue","volume":"219","author":"Dartois","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000242","DOI":"10.1136\/bmjresp-2017-000242","article-title":"British Thoracic Society Guideline for the Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD)","volume":"4","author":"Haworth","year":"2017","journal-title":"BMJ Open Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4046\/trd.2018.0060","article-title":"Treatment of Mycobacterium avium Complex Pulmonary Disease","volume":"82","author":"Kwon","year":"2019","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e0108822","DOI":"10.1128\/spectrum.01088-22","article-title":"Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease","volume":"10","author":"Zo","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_24","unstructured":"CLSI (2018). Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomycetes., Clinical and Laboratory Standards Institute. [3rd ed.]. CLSI standard M24."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/JCM.01936-09","article-title":"Evaluation of Mycobacterium avium Complex Clarithromycin Susceptibility Testing Using SLOMYCO Sensititre Panels and JustOne Strips","volume":"48","author":"Babady","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/jac\/dkz027","article-title":"Novel External Quality Assurance Scheme for Drug Susceptibility Testing of Non-Tuberculous Mycobacteria: A Multicentre Pilot Study","volume":"74","author":"Nikolayevskyy","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","unstructured":"EUCAST European Committee on Antimicrobial Susceptibility Testing (2022, October 10). Data from the EUCAST MIC Distribution Website. Available online: https:\/\/mic.eucast.org\/search\/."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lin, S., Hua, W., Wang, S., Zhang, Y., Chen, X., Liu, H., Shao, L., Chen, J., and Zhang, W. (2022). In Vitro Assessment of 17 Antimicrobial Agents against Clinical Mycobacterium avium Complex Isolates. BMC Microbiol., 22.","DOI":"10.1186\/s12866-022-02582-2"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ying, R., Yang, J., and Sha, W. (2022). Antimicrobial Susceptibility Testing Using MYCO Test-System and MIC Distribution of 8 Drugs against Clinical Isolates from Shanghai of Nontuberculous Mycobacteria. bioRxiv.","DOI":"10.1101\/2022.05.03.490561"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.36488\/cmac.2022.2.147-154","article-title":"Antimicrobial susceptibility of Mycobacterium avium complex mycobacteria isolated from patients in Ural Federal District of the Russian Federation","volume":"24","author":"Umpeleva","year":"2022","journal-title":"Clin. Microbiol. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.2147\/IDR.S332835","article-title":"In Vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China","volume":"14","author":"Yu","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fmicb.2020.00081","article-title":"Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing","volume":"11","author":"Aubry","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_33","first-page":"77","article-title":"Underutilization of Nontuberculous Mycobacterial Drug Susceptibility Testing in Ontario, Canada, 2010\u20132015","volume":"5","author":"Andrews","year":"2020","journal-title":"Off. J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Litvinov, V., Makarova, M., Galkina, K., Khachaturiants, E., Krasnova, M., Guntupova, L., and Safonova, S. (2018). Drug Susceptibility Testing of Slowly Growing Non-Tuberculous Mycobacteria Using Slomyco Test-System. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203108"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00491-18","DOI":"10.1128\/AAC.00491-18","article-title":"In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease","volume":"62","author":"Kwon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","first-page":"379.e1","article-title":"Differential Drug Susceptibility Patterns of Mycobacterium Chimaera and Other Members of the Mycobacterium avium-Intracellulare Complex","volume":"25","author":"Maurer","year":"2019","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jiac.2017.10.022","article-title":"Differences in Drug Susceptibility Pattern between Mycobacterium avium and Mycobacterium intracellulare Isolated in Respiratory Specimens","volume":"24","author":"Cho","year":"2018","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1128\/JCM.02127-14","article-title":"Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare","volume":"52","author":"Bernard","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_39","first-page":"332","article-title":"Antimicrobial Susceptibility and Molecular Characterization of Mycobacterium intracellulare in China","volume":"27","author":"Zhao","year":"2014","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/jac\/dkq536","article-title":"Evaluation of a Rapid Detection Method of Clarithromycin Resistance Genes in Mycobacterium avium Complex Isolates","volume":"66","author":"Inagaki","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","first-page":"411","article-title":"Activities of Linezolid against Nontuberculous Mycobacteria","volume":"30","author":"Cavusoglu","year":"2007","journal-title":"New Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10156-006-0457-8","article-title":"Relationship between Clinical Efficacy of Treatment of Pulmonary Mycobacterium avium Complex Disease and Drug-Sensitivity Testing of Mycobacterium avium Complex Isolates","volume":"12","author":"Kobashi","year":"2006","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1128\/AAC.36.12.2841","article-title":"Effect of PH on Radiometric MICs of Clarithromycin against 18 Species of Mycobacteria","volume":"36","author":"Rastogi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/AAC.38.2.381","article-title":"Identification of Mutations in 23S RRNA Gene of Clarithromycin-Resistant Mycobacterium intracellulare","volume":"38","author":"Meier","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1128\/AAC.39.12.2625","article-title":"Genetic Basis of Macrolide Resistance in Mycobacterium avium Isolated from Patients with Disseminated Disease","volume":"39","author":"Nash","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/JCM.00555-13","article-title":"Rapid Molecular Detection of Macrolide Resistance in the Mycobacterium avium Complex: Are We There Yet?","volume":"51","author":"Christianson","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e00943-16","DOI":"10.1128\/AAC.00943-16","article-title":"Selection of Resistance to Clarithromycin in Mycobacterium Abscessus Subspecies","volume":"61","author":"Mougari","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e00516-19","DOI":"10.1128\/JCM.00516-19","article-title":"GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium Abscessus and Determination of Clarithromycin and Amikacin Resistance","volume":"57","author":"Huh","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0221221","DOI":"10.1128\/aac.02212-21","article-title":"A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study","volume":"66","author":"Kaya","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1128\/AAC.49.6.2387-2398.2005","article-title":"Antimycobacterial Agents Differ with Respect to Their Bacteriostatic versus Bactericidal Activities in Relation to Time of Exposure, Mycobacterial Growth Phase, and Their Use in Combination","volume":"49","author":"Verbrugh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/infdis\/171.3.747","article-title":"Reduced Serum Levels of Clarithromycin in Patients Treated with Multidrug Regimens Including Rifampin or Rifabutin for Mycobacterium avium-M. Intracellulare Infection","volume":"171","author":"Wallace","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","article-title":"The Immunomodulatory Effects of Macrolide Antibiotics in Respiratory Disease","volume":"71","author":"Pollock","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jiac.2020.02.008","article-title":"Effective Treatment for Clarithromycin-Resistant Mycobacterium avium Complex Lung Disease","volume":"26","author":"Adachi","year":"2020","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_54","first-page":"149","article-title":"Resistance Mechanisms and Drug Susceptibility Testing of Nontuberculous Mycobacteria","volume":"15","author":"Boeree","year":"2012","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dks279","article-title":"Acquisition of Clarithromycin Resistance Mutations in the 23S RRNA Gene of Mycobacterium Abscessus in the Presence of Inducible Erm(41)","volume":"67","author":"Maurer","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.48.1.143-150.2004","article-title":"Molecular Basis of Intrinsic Macrolide Resistance in the Mycobacterium Tuberculosis Complex","volume":"48","author":"Dorson","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/jb.176.20.6192-6198.1994","article-title":"Ribosomal Protein Gene Sequence Changes in Erythromycin-Resistant Mutants of Escherichia Coli","volume":"176","author":"Chittum","year":"1994","journal-title":"J. Bacteriol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/j.1365-2958.2007.05975.x","article-title":"Novel Mutations in Ribosomal Proteins L4 and L22 That Confer Erythromycin Resistance in Escherichia Coli","volume":"66","author":"Zaman","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1365-2958.1990.tb00696.x","article-title":"Inducible Erythromycin Resistance in Staphylococci Is Encoded by a Member of the ATP-Binding Transport Super-Gene Family","volume":"4","author":"Ross","year":"1990","journal-title":"Mol. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7164\/antibiotics.41.142","article-title":"Involvement of Cell Impermeability in Resistance to Macrolides in Some Producer Streptomycetes","volume":"41","author":"Fierro","year":"1988","journal-title":"J. Antibiot."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e00924-17","DOI":"10.1128\/AAC.00924-17","article-title":"Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy","volume":"61","author":"Zimmerman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Nosova, E.Y., Zimenkov, D.V., Khakhalina, A.A., Isakova, A.I., Krylova, L.Y., Makarova, M.V., Galkina, K.Y., Krasnova, M.A., Safonova, S.G., and Litvinov, V.I. (2016). A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium Tuberculosis Isolates in Moscow, Russia. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167093"},{"key":"ref_63","unstructured":"WHO (2018). Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines Used in the Treatment of Drug-Resistant Tuberculosis, World Health Organization."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/jac\/dky268","article-title":"Distribution of Plasma Concentrations of First-Line Anti-TB Drugs and Individual MICs: A Prospective Cohort Study in a Low Endemic Setting","volume":"73","author":"Niward","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium Complex Lung Disease with a Little Help from My Friend","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","unstructured":"(2022). Antimycobacterial Susceptibility Testing Group Updating the Approaches to Define Susceptibility and Resistance to Anti-Tuberculosis Agents: Implications for Diagnosis and Treatment. Eur. Respir. J., 59, 2200166."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kim, H.-J., Lee, J.S., Kwak, N., Cho, J., Lee, C.-H., Han, S.K., and Yim, J.-J. (2019). Role of Ethambutol and Rifampicin in the Treatment of Mycobacterium avium Complex Pulmonary Disease. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0982-8"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e01787-19","DOI":"10.1128\/AAC.01787-19","article-title":"Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease","volume":"64","author":"Moon","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","first-page":"250","article-title":"Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-Tuberculous Mycobacterioses","volume":"70","author":"Schoenfeld","year":"2016","journal-title":"Pneumol. Stuttg. Ger."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"693369","DOI":"10.3389\/fphar.2021.693369","article-title":"Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A Meta-Analysis Study","volume":"12","author":"Hajikhani","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e00527-18","DOI":"10.1128\/AAC.00527-18","article-title":"Mutations in GyrA and GyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium Abscessus Complex Clinical Isolates","volume":"62","author":"Kim","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1128\/AAC.01761-09","article-title":"Moxifloxacin Pharmacokinetics\/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection","volume":"54","author":"Deshpande","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e01899-19","DOI":"10.1128\/AAC.01899-19","article-title":"Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug","volume":"64","author":"Reingewertz","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","unstructured":"World Health Organization (2021). Technical Report on Critical Concentrations for Drug Susceptibility Testing of Isoniazid and the Rifamycins (Rifampicin, Rifabutin and Rifapentine), World Health Organization."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0732-8893(88)90068-5","article-title":"Effects of Surface-Active Agents on Drug Susceptibility Levels and Ultrastructure of Mycobacterium avium Complex Organisms Isolated from AIDS Patients","volume":"11","author":"Naik","year":"1988","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_78","first-page":"208","article-title":"In Vitro and in Vivo Synergistic Effect of Isoniazid with Streptomycin and Clofazimine against Mycobacterium avium Complex (MAC)","volume":"75","author":"Reddy","year":"1994","journal-title":"Tuber. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.biochi.2006.05.017","article-title":"Crystal Structure of the Bacterial Ribosomal Decoding Site Complexed with Amikacin Containing the Gamma-Amino-Alpha-Hydroxybutyryl (Haba) Group","volume":"88","author":"Kondo","year":"2006","journal-title":"Biochimie"},{"key":"ref_80","unstructured":"WHO (2018). Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis, World Health Organization."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/AAC.45.9.2414-2419.2001","article-title":"Aminoglycoside Resistance with Homogeneous and Heterogeneous Populations of Antibiotic-Resistant Ribosomes","volume":"45","author":"Recht","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The Role of Amikacin in the Treatment of Nontuberculous Mycobacterial Disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S RRNA Gene Mutation in Treated Isolates","volume":"51","author":"Iakhiaeva","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1038\/s41598-021-85721-5","article-title":"Association between 16S RRNA Gene Mutations and Susceptibility to Amikacin in Mycobacterium avium Complex and Mycobacterium Abscessus Clinical Isolates","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid Pharmacokinetics and Pharmacodynamics in Clinical Treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.47.5.1736-1738.2003","article-title":"In Vitro Activity of Linezolid against Slowly Growing Nontuberculous Mycobacteria","volume":"47","author":"Crist","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria","volume":"55","author":"Wallace","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/clinids\/19.1.211","article-title":"Prophylactic Effect of Co-Trimoxazole for Mycobacterium avium Complex Infection: A Previously Unreported Benefit","volume":"19","author":"Fraser","year":"1994","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkt400","article-title":"Serum Concentration of Co-Trimoxazole during a High-Dosage Regimen","volume":"69","author":"Rolain","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e00834-19","DOI":"10.1128\/JCM.00834-19","article-title":"Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria","volume":"57","author":"Woods","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.chest.2020.11.007","article-title":"You Gotta Make Me See, What Does It Mean to Have an MIC?","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4103\/ijmy.ijmy_219_21","article-title":"Evaluation of Drug Susceptibility in Nontuberculous Mycobacteria Using the SLOMYCO and RAPMYCO Sensititre Plates","volume":"10","author":"Pedace","year":"2021","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jgar.2022.05.027","article-title":"Identification and Drug Susceptibility Testing of the Subspecies of Mycobacterium avium Complex Clinical Isolates in Mainland China","volume":"31","author":"Li","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e0119421","DOI":"10.1128\/mSystems.01194-21","article-title":"Comparative Genomics of Mycobacterium avium Complex Reveals Signatures of Environment-Specific Adaptation and Community Acquisition","volume":"6","author":"Keen","year":"2021","journal-title":"mSystems"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/AAC.50.2.461-468.2006","article-title":"The Two-Component Regulatory System MtrAB Is Required for Morphotypic Multidrug Resistance in Mycobacterium avium","volume":"50","author":"Cangelosi","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1099\/00221287-147-3-527","article-title":"Phenotypic Consequences of Red-White Colony Type Variation in Mycobacterium avium","volume":"147","author":"Cangelosi","year":"2001","journal-title":"Microbiol. Read. Engl."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment","volume":"186","author":"Egelund","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/AAC.35.9.1824","article-title":"Bactericidal Effects of Antibiotics on Slowly Growing and Nongrowing Bacteria","volume":"35","author":"Eng","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1073\/pnas.1719504115","article-title":"Robust, Linear Correlations between Growth Rates and \u03b2-Lactam-Mediated Lysis Rates","volume":"115","author":"Lee","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_101","first-page":"77","article-title":"Growth and Cell Division of Mycobacterium avium","volume":"126","author":"Rastogi","year":"1981","journal-title":"J. Gen. Microbiol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Pullan, S.T., Allnutt, J.C., Devine, R., Hatch, K.A., Jeeves, R.E., Hendon-Dunn, C.L., Marsh, P.D., and Bacon, J. (2016). The Effect of Growth Rate on Pyrazinamide Activity in Mycobacterium Tuberculosis\u2014Insights for Early Bactericidal Activity?. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1533-z"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/1040841X.2018.1425672","article-title":"On the Intrinsic Constraint of Bacterial Growth Rate: M. Tuberculosis\u2019s View of the Protein Translation Capacity","volume":"44","author":"Zhu","year":"2018","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"00466","DOI":"10.1183\/23120541.00466-2021","article-title":"Treatment of Severe Mycobacterium avium Complex Pulmonary Disease with Adjunctive Amikacin and Clofazimine versus Standard Regimen Alone: A Retrospective Study","volume":"7","author":"Zweijpfenning","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e01798-16","DOI":"10.1128\/AAC.01798-16","article-title":"In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex","volume":"61","author":"Philley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e00665-19","DOI":"10.1128\/AAC.00665-19","article-title":"In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates","volume":"63","author":"Kim","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1099\/jmm.0.001025","article-title":"In Vitro Activity of Bedaquiline against Slow-Growing Nontuberculous Mycobacteria","volume":"68","author":"Martin","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Litvinov, V., Makarova, M., Kudlay, D., Nikolenko, N., and Mikhailova, J. (2021). In Vitro Activity of Bedaquiline against Mycobacterium avium Complex. J. Med. Microbiol., 70.","DOI":"10.1099\/jmm.0.001439"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/AAC.00031-19","article-title":"In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China","volume":"63","author":"Yu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e02627-16","DOI":"10.1128\/AAC.02627-16","article-title":"In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/12\/1756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:33:56Z","timestamp":1760146436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/12\/1756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":110,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["antibiotics11121756"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11121756","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,4]]}}}